Esperion Therapeutics (ESPR) said Thursday the US Food and Drug Administration has confirmed that it has enough data to proceed with phase 3 studies of bempedoic acid as a monotherapy and in combination with ezetimibe in children with heterozygous and homozygous familial hypercholesterolemia.
The company said it plans to begin phase 3 trials this year and apply for an additional six-month patent extension through June 2031.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.